Attorney's Docket No.: 06666-022002 / USC 2862B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Noriyuki Kasahara, et al.

Art Unit : 1633

Serial No.: 10/045,178

Examiner: Ileana Popa

Filed

: January 11, 2002

Title

: GENE DELIVERY SYSTEM AND METHODS OF USE

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the reference listed on the attached PTO-1449 form. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance. A check for \$180 in payment of the late submission fee of §1.17(p) is enclosed. Please apply any other charges or credits to Deposit Account No. 06-1050.

03/21/2006 HLE333

00000009 10045178

01 FC:1806

180.00 OP

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

March 16, 2006	
Date of Deposit	
Melissa alexander	
Signature	
Melissa Alexander	

Typed or Printed Name of Person Signing Certificate

Applicant: Noriyuki Kasahara et al.

Serial No.: 10/045,178 Filed : January 11, 2002

Page

: 2 of 2

Attorney's Docket No.: 06666-022002 / USC 2862B

By citing the above reference, Applicants do not acquiesce or admit that this document is "prior art" under 35 U.S.C. Applicants specifically reserve the right, where appropriate, to antedate the cited document by an appropriate showing under 37 C.F.R. § 1.131, § 1.604, § 1.608 or any other suitable means.

Respectfully submitted,

Reg. No. 44,164

Fish & Richardson P.C. 500 Arguello Street, Suite 500 Redwood City, California 94063 Telephone: (650) 839-5070

Facsimile: (650) 839-5071

50333541.doc

0	ILE
	- 88
A MAR	2 0 2006
TEXT CAN	Substitute Form

(37 CFR §1.98(b))

Sheet	1	of	1	

PTO-1449

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 06666-022002 / USC 2862B

Application No.

10/045,178

Supplemental Information Disclosure Statement by Applicant

Applicant

(Use several she	ets if necessary)	
------------------	-------------------	--

Noriyuki Kasahara, et al.

Filing Date

Group Art Unit 1633

January 11, 2002 **U.S. Patent Documents** Publication Desig. Examiner Document Filing Date Initial ID Number Date Patentee Subclass If Appropriate Class AAAB ACAD AE AF AG AΗ ΑI ΑJ AK

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass		slation No
	AL							
	AM							
	AN							
	AO				<u> </u>		_	
	AP							

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.			
Initial	ID	Document		
	AQ	Cavazzana-Calvo, M., et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 288(5466):669-672.		
	AR			
	AS			
	AT			

Examiner Signature	Date Considered			
	Date Considered			
EVANINED. Laws and a second of the second of				
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with				
next communication to applicant				